Table 2.
Multivariable analyses for ORR, PFS and OS in pembrolizumab cohort considering GRImT1 as independent variable.
| Test Variables | ORR OR (95% CI) | p-Value | PFS HR (95% CI) | p-Value | OS HR (95% CI) | p-Value |
|---|---|---|---|---|---|---|
| GRImT1 low (ref.)/high | 0.79 (0.52–1.20) | 0.29 | 3.05 (1.42–6.54) | <0.01 a | 2.63 (1.18–5.86) | 0.01 a |
| Never smokers (ref.)/ Current-former smokers |
1.19 (0.71–1.96) | 0.50 | 0.97 (0.29–3.26) | 0.96 | 0.41 (0.12–1.44) | 0.16 |
| ECOG PS 0–1 (ref.)/≥2 | 0.83 (0.57–1.20) | 0.34 | 1.29 (0.61–2.72) | 0.49 | 1.14 (0.46–2.81) | 0.76 |
| Non adenocarcinoma (ref.)/ Adenocarcinoma |
0.71 (0.49–1.02) | 0.07 | – | – | – | – |
| Metastatic sites ≤2/>2 | – | – | 2.18 (1.14–4.17) | 0.02 a | 1.75 (0.88–3.49) | 0.10 |
| PD-L1 percentage <78/≥78 | 1.32 (1.02–1.71) | 0.04 a | – | – | – | – |
| Liver metastases No. (ref.)/Yes | – | – | 1.24 (0.52–2.96) | 0.61 | – | – |
| Bone metastases No. (ref.)/Yes | 0.79 (0.59–1.06) | 0.12 | – | – | – | – |
CI, confidence interval; ORR, objective response rate; OR, odds ratio; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; GRImT1, GRIm-Score 45 days since treatment initiation; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death-ligand 1; No., number. a Statistically significant (p < 0.05).